PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)

Detalles Bibliográficos
Autores principales: Mascarenhas, John, Harrison, Claire, Kiladjian, Jean-Jacques, Sockel, Katja, Vannucchi, Alessandro, Berry, Tymara, Redding, Denise, Sherman, Laurie, Dougherty, Souria, Peng, Lixian, Sun, Libo, Huang, Fei, Wan, Ying, Rodolf, Vivian, Ho, Judy, Navada, Shyamala, Komrokji, Rami S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429542/
http://dx.doi.org/10.1097/01.HS9.0000975644.99899.f4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429542/
http://dx.doi.org/10.1097/01.HS9.0000975644.99899.f4

Ejemplares similares